ProKidney Corp. Class A Ordinary Shares

PROK XNAS • BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

310M

Short interest (Jul 15)

10.2%

Net Short (Jul 27 ): 0.0%

Borrow Fee

13.85%

↓ 18.0%

Available Shares

↑ 185.6%

Price Chart

Company Overview

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Company Info

Exchange: NASDAQ

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

CIK: 0001850270

Asset Type: CS

Market Data

Market Cap: $307,799,569

Employees: 231

Status: Active

Short Interest

Current Borrow Fee 13.85%

Range: 8.98% - 13.85%

Available Shares 4M

Range: 60K - 3.8M

Recent Changes

Fee Change: ↓ 11.2%

Available Change: ↑ 640.0%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime